BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240325
DTEND;VALUE=DATE:20240328
DTSTAMP:20260516T003930
CREATED:20231115T103534Z
LAST-MODIFIED:20231115T103534Z
UID:38132-1711324800-1711583999@www.pharmajournalist.com
SUMMARY:6th Neuroimmunology Drug Development Summit
DESCRIPTION:Neuroimmunology targets in neurodegeneration are hotter than ever. Capturing biopharma’s latest research spanning discovery to early clinical development\, the 6th Neuroimmunology Drug Development Summit is the industry-choice\, comprehensive forum dedicated to translating neuroinflammatory-targeted therapeutics into clinical trials. \nWhat are the top features to look forward to in 2024? \n\nDoubled pre-conference workshop content\, with 6 deep-dive sessions tailored to your discovery biology and translational expertise led by neuroimmunology leaders from Lundbeck\, Sanofi\, Merck\, Regeneron\, and more\nAgenda content spotlighted neurodegeneration – including TREM2 clinical data updates and breaking down trial design and rationale with Alector and Vigil Neuroscience\nNew case studies beyond microglia\, with sessions spearheading astrocyte function and therapeutic intervention from Sanofi\, IMNEWRUN\, and UCL\nBrand-new content on immunocompetent brain organoids to recapitulate and investigate complex neuroimmune interactions with Roche and Herophilus\nIt is the biggest and most comprehensive program to date\, with 38+ industry and academic speakers\, including new presenting companies Eisai\, EMD Serono\, Ventus Therapeutics\, PTC Therapeutics\, and Inflammasome Therapeutics\n\nUniting 100+ all-star leaders across industry and academia\, this is the must-attend forum for anyone working on treatments targeting neuroinflammation across neurological indications and looking to accelerate their candidates into the clinic in 2024. \nTo know more visit: https://ter.li/wb3bhh
URL:http://www.pharmajournalist.com/event/6th-neuroimmunology-drug-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240325
DTEND;VALUE=DATE:20240328
DTSTAMP:20260516T003930
CREATED:20231120T150249Z
LAST-MODIFIED:20231120T150249Z
UID:38186-1711324800-1711583999@www.pharmajournalist.com
SUMMARY:5th Supply Chain & Logistics for Cell Therapies Summit
DESCRIPTION:As the cell therapy field rapidly expands\, keeping ahead of the race by creating a visible and robust supply chain has never been more critical to ensure you have the skills and strategy to develop into the next stage of your pipeline. \nJoin us at the 5th Supply Chain & Logistics for Cell Therapies Summit in Boston from March 25-27th. This summit will bring together logistics and clinical operations experts to establish standardized best practices in planning\, communication and assist companies in scaling up to consistently deliver cell therapies safely\, on time\, and in a cost-effective process. \nSeize the opportunity to enhance your expertise in cell therapy logistics by connecting with leaders in clinical operations\, including esteemed companies like Beam Therapeutics\, Lovance\, Arcellx\, Jassen Pharmaceuticals\, and more. \nDownload the event guide to learn more: https://ter.li/d6jto3
URL:http://www.pharmajournalist.com/event/5th-supply-chain-logistics-for-cell-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240326
DTEND;VALUE=DATE:20240329
DTSTAMP:20260516T003930
CREATED:20231107T111306Z
LAST-MODIFIED:20231107T111306Z
UID:38097-1711411200-1711670399@www.pharmajournalist.com
SUMMARY:5th Glioblastoma Drug Development Summit
DESCRIPTION:The 5th Glioblastoma Drug Development Summit is the only industry led forum for large pharma\, biotech\, neuro-oncologists and academic KOLs to unite alongside a dedicated panel of investors under the common goal to breakthrough GBM barriers to accelerate the practical translation and clinical development of emerging therapeutics for glioblastoma and CNS tumor patients. \nDiscover innovative approaches to surpassing the blood-brain barrier to unlock previously uncovered therapeutic potential\, keep ahead of the latest clinical trial design rationale and navigate the regulatory landscape for novel combination therapies with actionable insights to improve clinical success. \nWith promising clinical readouts from a range of therapeutic modalities\, novel drug targets emerging and positive advances in state-of-the-art technologies like sonodynamic therapy\, there is more potential than ever before to be unlocked within the GBM space. \nTo elevate your current standards\, join this unique collaboration between industry giants such as Novartis\, pioneering biotechs such as Day One Biopharmaceuticals\, world-renowned academics and investors. Embrace positive clinical outcomes alongside a dedicated community committed to defeating GBM/CNS tumors and transforming lives. \nAccess the complete agenda here including a packed pre-workshop conference day\, panel discussions\, poster sessions and important networking opportunities.
URL:http://www.pharmajournalist.com/event/5th-glioblastoma-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240326
DTEND;VALUE=DATE:20240328
DTSTAMP:20260516T003930
CREATED:20231201T114649Z
LAST-MODIFIED:20231201T143620Z
UID:38253-1711411200-1711583999@www.pharmajournalist.com
SUMMARY:Pharma USA 2024
DESCRIPTION:Accelerate patient value. Pioneer healthcare’s transformation.  \nHealthcare reforms are finally paving the way to affordable access to medicines\, yet this progress threatens the development of future life-saving therapies. The moment is now to prove ourselves as a trusted industry ally and the ultimate safe harbor for patients. \nThe key? Delivering aligned value to HCPs\, patients\, payers and regulators. \nSpeed and scale is non-negotiable. Those afraid to accelerate will be left behind. We must adapt to evolving payer needs\, empower HCPs with crucial insights\, bridge regulatory gaps and co-create with patients. Only then will we achieve exceptional outcomes. \nReuters Events: Pharma USA 2024 is where senior pharma executives from Commercial\, Marketing\, Medical Affairs\, RWE\, Market Access\, Patient Engagement\, as well as key stakeholders\, will come together to map out how they can deliver value to overcome the challenges that are hindering scientific innovation. \nJoin over 1\,200 of North America’s pharma pioneers\, leading solutions provider\, and patient advocates to sharpen short-term strategy and unite for a long-term future to exceed stakeholder desires across the value chain. \nTo know more visit: https://bit.ly/3GpdsrU
URL:http://www.pharmajournalist.com/event/pharma-usa-2024/
LOCATION:Pennsylvania Convention Center\, 1101 Arch Street\, Philadelphia\, PA\, 19107\, United States
ORGANIZER;CN="Reuters Events":MAILTO:Kana.Hutton@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240326
DTEND;VALUE=DATE:20240330
DTSTAMP:20260516T003930
CREATED:20240103T114154Z
LAST-MODIFIED:20240103T114154Z
UID:38420-1711411200-1711756799@www.pharmajournalist.com
SUMMARY:7th Gene Therapy for Rare Disorders Summit
DESCRIPTION:This past year has seen more gene therapies approved by the FDA than the previous five years combined\, and almost triple the number of clinical trials in gene therapy have been initiated in H1 of 2023 compared to the same time frame in the previous year. \nTo maximize the value of your late-stage gene therapy assets\, the 7th Gene Therapy for Rare Disorders Summit is returning to tackle head-on the significant clinical\, manufacturing\, regulatory\, and commercial challenges facing gene therapy programs today. \nBringing together key figures from industry\, regulatory bodies\, patient non-profits\, payers\, and key service providers\, this is the field’s foremost meeting for collectively progressing rare gene therapy programs into and through the clinic. \nJoin us to leverage essential insights from over 300 peers from leading biopharma companies with direct experience in driving gene therapies through the clinic and into the market. Keep your finger on the pulse\, form connections with top decision-makers\, and address your specific clinical\, manufacturing\, regulatory\, and commercial bottlenecks to safeguard against costly delays and progress your gene therapies through the pipeline quickly and safely. \nTo know more visit: https://ter.li/x4qqur
URL:http://www.pharmajournalist.com/event/7th-gene-therapy-for-rare-disorders-summit/
LOCATION:The Westin Copley Place\, 10 Huntington Avenue\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR